Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon-alpha Omniferon - Viragen

Drug Profile

Interferon-alpha Omniferon - Viragen

Alternative Names: alpha-IF; Natural human interferon-alpha; Natural human leukocyte interferon-alpha; Omniferon

Latest Information Update: 04 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Viragen; ViraNative
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Haematological malignancies; Hepatitis C; Herpes simplex virus infections; HIV infections; Leukaemia; Multiple sclerosis

Most Recent Events

  • 28 Sep 2001 Suspended-II for Hepatitis C in Europe (SC)
  • 29 Jun 2001 Viragen has received UK approval to begin clinical trials with OmniferonTM for the treatment of multiple sclerosis
  • 09 Feb 2001 Pall Corporation will supply leukocytes fo Viragen for manufacture of OmniferonTM
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top